PL361272A1 - A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease - Google Patents
A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's diseaseInfo
- Publication number
- PL361272A1 PL361272A1 PL36127201A PL36127201A PL361272A1 PL 361272 A1 PL361272 A1 PL 361272A1 PL 36127201 A PL36127201 A PL 36127201A PL 36127201 A PL36127201 A PL 36127201A PL 361272 A1 PL361272 A1 PL 361272A1
- Authority
- PL
- Poland
- Prior art keywords
- galantamine
- alzheimer
- disease
- treatment
- behaviour associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19425900P | 2000-04-03 | 2000-04-03 | |
| PCT/EP2001/003553 WO2001074339A2 (fr) | 2000-04-03 | 2001-03-28 | Utilisation de la galantamine dans le traitement du comportement neuropsychiatrique associe a la maladie d'alzheimer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL361272A1 true PL361272A1 (en) | 2004-10-04 |
Family
ID=22716898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL36127201A PL361272A1 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1272192A2 (fr) |
| JP (1) | JP2003528913A (fr) |
| KR (1) | KR20020086911A (fr) |
| CN (1) | CN1430514A (fr) |
| AU (2) | AU2001265844B2 (fr) |
| BG (1) | BG107093A (fr) |
| BR (1) | BR0109770A (fr) |
| CA (1) | CA2310926C (fr) |
| CZ (1) | CZ20023543A3 (fr) |
| EE (1) | EE200200554A (fr) |
| HR (1) | HRP20020778A2 (fr) |
| HU (1) | HUP0300566A3 (fr) |
| IL (1) | IL152061A0 (fr) |
| MX (1) | MXPA02009777A (fr) |
| NO (1) | NO20024746L (fr) |
| PL (1) | PL361272A1 (fr) |
| RU (1) | RU2002129298A (fr) |
| SK (1) | SK15422002A3 (fr) |
| WO (1) | WO2001074339A2 (fr) |
| ZA (1) | ZA200207935B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| ES2293287T3 (es) * | 2003-07-25 | 2008-03-16 | F. Hoffmann-La Roche Ag | Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos. |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| JP5647099B2 (ja) | 2008-03-27 | 2014-12-24 | チェイス・ファーマスーティカルズ・コーポレーション | 認知症を治療するための使用及び組成物 |
| WO2013160728A1 (fr) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Composés à double ciblage pour le traitement de la maladie d'alzheimer |
| BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
| WO2016187339A1 (fr) * | 2015-05-18 | 2016-11-24 | Synaptec Development Llc | Clairance de galantamine d'amyloides |
| WO2023036105A1 (fr) * | 2021-09-09 | 2023-03-16 | 上海日馨医药科技股份有限公司 | Méthode de traitement d'une maladie neurodégénérative |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
| US7939522B1 (en) | 1998-11-23 | 2011-05-10 | Bonnie M Davis | Dosage formulations for acetylcholinesterase inhibitors |
| AU775914B2 (en) * | 1998-12-24 | 2004-08-19 | Janssen Pharmaceutica N.V. | Controlled release galantamine composition |
| CA2310950C (fr) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | Posologie de galantamine efficace qui reduit les effets secondaires |
| CA2310990A1 (fr) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | Utilisation de la galantamine pour le traitement de la maladie d'alzheimer; ciblage de la cause sous-jacente de la maladie |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/fr not_active Expired - Lifetime
-
2001
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/fr not_active Application Discontinuation
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Application Discontinuation
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 EP EP01943200A patent/EP1272192A2/fr not_active Withdrawn
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200207935B (en) | 2004-01-30 |
| EP1272192A2 (fr) | 2003-01-08 |
| NO20024746L (no) | 2002-11-28 |
| MXPA02009777A (es) | 2003-03-27 |
| KR20020086911A (ko) | 2002-11-20 |
| WO2001074339A2 (fr) | 2001-10-11 |
| WO2001074339A3 (fr) | 2002-09-12 |
| RU2002129298A (ru) | 2004-03-27 |
| AU2001265844B2 (en) | 2005-04-14 |
| CN1430514A (zh) | 2003-07-16 |
| HRP20020778A2 (en) | 2004-04-30 |
| NO20024746D0 (no) | 2002-10-02 |
| SK15422002A3 (sk) | 2003-04-01 |
| HUP0300566A3 (en) | 2004-10-28 |
| BR0109770A (pt) | 2003-02-04 |
| BG107093A (bg) | 2003-06-30 |
| JP2003528913A (ja) | 2003-09-30 |
| CA2310926C (fr) | 2002-10-15 |
| IL152061A0 (en) | 2003-05-29 |
| EE200200554A (et) | 2004-04-15 |
| CZ20023543A3 (cs) | 2003-03-12 |
| CA2310926A1 (fr) | 2000-10-04 |
| AU6584401A (en) | 2001-10-15 |
| HUP0300566A2 (hu) | 2003-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL153214A0 (en) | Compounds to treat alzheimer's disease | |
| PT2264018E (pt) | Derivados de tioflavina para uso no diagnóstico da doença de alzheimer | |
| EP1043991A4 (fr) | Traitement contre la maladie d'alzheimer | |
| AU2001273132A1 (en) | Compounds to treat alzheimer's disease | |
| HUP0103838A3 (en) | Alzheimer's disease secretase | |
| AU2001233299A1 (en) | Methods for treating alzheimer's disease | |
| SI1303272T1 (sl) | Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni | |
| AU2001278084A1 (en) | Model for alzheimer's disease and other neurodegenerative diseases | |
| EP1007048A4 (fr) | Identification d'agents utiles dans le traitement de la maladie d'alzheimer | |
| HUP0301710A3 (en) | Radiopharmaceuticals for diagnosing alzheimer's disease | |
| AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
| NO20001869D0 (no) | Fremgangsmõte for behandling av Alzheimerssykdom | |
| AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
| AU2001236592A1 (en) | Methods for diagnosis of alzheimer's disease | |
| HRP20020778A2 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| HUP9903213A3 (en) | Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producing a pharmaceutical preparation intended for treatment of the alzheimer's disease | |
| GB0011410D0 (en) | Therapeutic combination for treating Alzheimer's disease | |
| AU2003303141A8 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease | |
| GB0011408D0 (en) | Therapeutic combination for treating Alzheimer's Disease | |
| AU2001248760A1 (en) | Preventives/remedies for alzheimer's disease | |
| EP1181550A4 (fr) | Procedes d'identification de composes pour le traitement de la maladie d'alzheimer | |
| AU2001246518A1 (en) | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease | |
| AU2001267826A1 (en) | Remedies for alzheimer's disease | |
| AU2002364885A8 (en) | Alzheimer's disease model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |